Literature DB >> 31544308

Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis.

I Jane Cox1,2, Ramazan Idilman3, Andrew Fagan4, Dilara Turan3, Lola Ajayi1,2, Adrien D Le Guennec5, Simon D Taylor-Robinson6, Fatih Karakaya3, Edith Gavis4, R Andrew Atkinson5, Roger Williams1,2, Masoumeh Sikaroodi7, Shahzor Nizam7, Patrick M Gillevet7, Jasmohan S Bajaj4.   

Abstract

BACKGROUND & AIMS: Dietary changes can modulate gut microbiota and interact with cirrhosis. Our prior study demonstrated that microbial diversity was higher in cirrhotics from Turkish vs the USA, which was associated with lower risk of 90-day hospitalizations. We aimed to define gut microbial functional and metabolomic changes to increase insight into benefits of the Mediterranean compared to Western diets.
METHODS: In all, 139 Turkish (46 controls/50 compensated/43 decompensated) and 157 American subjects (48 controls/59 compensated/50 decompensated) were studied. Turkish subjects consumed a modified Mediterranean diet with daily fermented milk intake, whereas Americans consumed a Western diet. Predicted gut microbial functionalities and plasma metabolomics were compared between/within countries. Correlation network differences between microbiota and metabolites in cirrhotics from Turkey vs the USA were evaluated.
RESULTS: Predicted microbial function showed lower amino acid, bioenergetics and lipid pathways, with functions related to vitamin B, glycan, xenobiotic metabolism, DNA/RNA synthesis, in cirrhotics from Turkey compared to the USA. Plasma metabolomics demonstrated higher relative lactate levels in Turkey vs the USA. The metabolite changes in decompensated cirrhosis, compared to controls, showed similar trends in Turkey and the USA, with reduced lipids and phosphocholines. Phosphocholines were significantly lower in patients hospitalized in 90 days (P = .03). Correlation networks in cirrhotics demonstrated linkage differences between beneficial taxa, Blautia and Oscillispira, and lactate and unsaturated lipids, in Turkey compared to American patients.
CONCLUSIONS: A modified Mediterranean diet was associated with altered plasma metabolomics and beneficially alters microbiota functionality and correlations compared to Western diet in cirrhosis. These altered diet-microbial interactions could potentially affect the 90-day hospitalization risk.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Mediterranean diet; Western diet; cirrhosis; fermented milk products; gut microbial function; metabolomics

Mesh:

Year:  2019        PMID: 31544308      PMCID: PMC6980909          DOI: 10.1111/liv.14256

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   8.754


  32 in total

Review 1.  You are what you eat: diet, health and the gut microbiota.

Authors:  Niv Zmora; Jotham Suez; Eran Elinav
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-01       Impact factor: 46.802

2.  Characterization of fecal microbial communities in patients with liver cirrhosis.

Authors:  Yanfei Chen; Fengling Yang; Haifeng Lu; Baohong Wang; Yunbo Chen; Dajiang Lei; Yuezhu Wang; Baoli Zhu; Lanjuan Li
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

3.  Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis.

Authors:  Jasmohan S Bajaj; Chathur Acharya; Andrew Fagan; Melanie B White; Edith Gavis; Douglas M Heuman; Phillip B Hylemon; Michael Fuchs; Puneet Puri; Mitchell L Schubert; Arun J Sanyal; Richard K Sterling; Todd R Stravitz; Mohammad S Siddiqui; Velimir Luketic; Hannah Lee; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Am J Gastroenterol       Date:  2018-06-06       Impact factor: 10.864

4.  The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis.

Authors:  Zhaoyu Li; Luis B Agellon; Theresa M Allen; Masato Umeda; Larry Jewell; Andrew Mason; Dennis E Vance
Journal:  Cell Metab       Date:  2006-05       Impact factor: 27.287

5.  Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls.

Authors:  Benjamin Heidrich; Marius Vital; Iris Plumeier; Nico Döscher; Silke Kahl; Janina Kirschner; Szilvia Ziegert; Philipp Solbach; Henrike Lenzen; Andrej Potthoff; Michael Peter Manns; Heiner Wedemeyer; Dietmar Helmut Pieper
Journal:  Liver Int       Date:  2017-06-20       Impact factor: 5.828

Review 6.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

Review 7.  Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health.

Authors:  David Ríos-Covián; Patricia Ruas-Madiedo; Abelardo Margolles; Miguel Gueimonde; Clara G de Los Reyes-Gavilán; Nuria Salazar
Journal:  Front Microbiol       Date:  2016-02-17       Impact factor: 5.640

8.  The gut microbiota promotes hepatic fatty acid desaturation and elongation in mice.

Authors:  Alida Kindt; Gerhard Liebisch; Thomas Clavel; Dirk Haller; Gabriele Hörmannsperger; Hongsup Yoon; Daniela Kolmeder; Alexander Sigruener; Sabrina Krautbauer; Claudine Seeliger; Alexandra Ganzha; Sabine Schweizer; Rosalie Morisset; Till Strowig; Hannelore Daniel; Dominic Helm; Bernhard Küster; Jan Krumsiek; Josef Ecker
Journal:  Nat Commun       Date:  2018-09-14       Impact factor: 14.919

9.  MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis.

Authors:  Jasmine Chong; Othman Soufan; Carin Li; Iurie Caraus; Shuzhao Li; Guillaume Bourque; David S Wishart; Jianguo Xia
Journal:  Nucleic Acids Res       Date:  2018-07-02       Impact factor: 16.971

10.  Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis.

Authors:  Mark J W McPhail; Debbie L Shawcross; Matthew R Lewis; Iona Coltart; Elizabeth J Want; Charalambos G Antoniades; Kiril Veselkov; Evangelos Triantafyllou; Vishal Patel; Oltin Pop; Maria Gomez-Romero; Michael Kyriakides; Rabiya Zia; Robin D Abeles; Mary M E Crossey; Wayel Jassem; John O'Grady; Nigel Heaton; Georg Auzinger; William Bernal; Alberto Quaglia; Muireann Coen; Jeremy K Nicholson; Julia A Wendon; Elaine Holmes; Simon D Taylor-Robinson
Journal:  J Hepatol       Date:  2016-01-18       Impact factor: 25.083

View more
  4 in total

Review 1.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

2.  Interaction of Microbiome, Diet, and Hospitalizations Between Brazilian and American Patients With Cirrhosis.

Authors:  Mario R Álvares-da-Silva; Claudia P Oliveira; Andrew Fagan; Larisse Longo; Rutiane U Thoen; Patricia M Yoshimura Zitelli; Renee M Tanaka Ferreira; Sara Mcgeorge; Amirhossein Shamsaddini; Alberto Q Farias; Masoumeh Sikaroodi; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2021-04-02       Impact factor: 11.382

Review 3.  Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2020-11-28       Impact factor: 33.883

4.  Dietary Protein, Fiber and Coffee Are Associated with Small Intestine Microbiome Composition and Diversity in Patients with Liver Cirrhosis.

Authors:  Shehnaz K Hussain; Tien S Dong; Vatche Agopian; Joseph R Pisegna; Francisco A Durazo; Pedram Enayati; Vinay Sundaram; Jihane N Benhammou; Mazen Noureddin; Gina Choi; Walid S Ayoub; Venu Lagishetty; David Elashoff; Marc T Goodman; Jonathan P Jacobs
Journal:  Nutrients       Date:  2020-05-13       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.